Article

Subscriber access provided by CORNELL UNIVERSITY LIBRARY

Enantioselective Construction of Tetrahydroquinolin-5one-based Spirooxindole Scaffold via An Organocatalytic Asymmetric Multicomponent [3+3] Cyclization

Qiu-Ning Zhu, Yu-Chen Zhang, Meng-Meng Xu, Xiao-Xue Sun, Xue Yang, and Feng Shi J. Org. Chem., Just Accepted Manuscript • DOI: 10.1021/acs.joc.6b01598 • Publication Date (Web): 15 Aug 2016 Downloaded from http://pubs.acs.org on August 15, 2016

Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.



The Journal of Organic Chemistry is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036

Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Enantioselective Construction of Tetrahydroquinolin-5-one-based Spirooxindole Scaffold via An Organocatalytic Asymmetric Multicomponent [3+3] Cyclization

Qiu-Ning Zhu,[‡] Yu-Chen Zhang,[‡] Meng-Meng Xu, Xiao-Xue Sun, Xue Yang and Feng Shi*

School of Chemistry & Chemical Engineering, and Jiangsu Key Laboratory of Green Synthetic

Chemistry for Functional Materials, Jiangsu Normal University, Xuzhou, 221116, China

E-mail: fshi@jsnu.edu.cn

[‡]These authors contributed equally to the work.



Abstract: The first catalytic enantioselective construction of biologically important tetrahydroquinolin-5-one-based spirooxindole has been developed via chiral cinchona alkaloid-catalyzed asymmetric three-component [3+3] cyclization of cyclic enaminone, isatin, and malononitrile, which afforded a series of tetrahydroquinolin-5-one-based spirooxindoles in high yields and with excellent enantioselectivities (up to 99% yield, 97:3 er). This reaction could be applicable to large-scale synthesis of enantioenriched tetrahydroquinolin-5-one-based spirooxindoles. This synthetic methodology will not only provide a unique approach for the construction of chiral tetrahydroquinolin-5-one-based spirooxindole scaffolds but also increase our understanding of catalytic enantioselective multicomponent reactions.

Introduction

Spirooxindole represents one of the most important heterocyclic frameworks, which constitutes the core structures of many natural alkaloids and pharmaceuticals.¹⁻² Among the large family of spirooxindoles, tetrahydroquinolin-5-one-based spirooxindoles exhibit a wide spectrum of bioactivities such as antimicrobial,^{3a} cytotoxic to MCF-7,^{3a} lifespan-altering,^{3b} antioxidant^{4a}, and inhibiting alanyl aminopeptidase^{4b} (Figure 1). Consequently, the construction of such spiro-frameworks has received much attention from chemists. However, all established methods focus on the synthesis of racemic tetrahydroquinolin-5-one-based spirooxindoles.⁵ *In sharp contrast, no catalytic asymmetric approaches are available for synthesizing such biologically important chiral spirooxindoles.* Nevertheless, the enantioselective construction of bioactivities compared with the racemates.⁶ Thus, it is important to develop catalytic enantioselective approaches for the construction of chiral tetrahydroquinolin-5-one-based spirooxindole scaffolds.



Figure 1. Selected bioactive tetrahydroquinolin-5-one-based spirooxindoles.

In recent years, due to the significance of chiral spirooxindoles in medicinal chemistry, numerous catalytic asymmetric reactions have been developed rapidly for the enantioselective

construction of a wide range of structurally diversified spirooxindole skeletons (Scheme 1, eq. 1).⁷⁻⁸ *Despite these recent advances in this research field, the catalytic enantioselective construction of tetrahydroquinolin-5-one-based spirooxindole scaffold remains underdeveloped* (eq. 2). This may be associated with challenges in enantioselectively constructing this framework, such as the design of the enantioselective reaction, the selection of chiral catalysts based on the reaction mechanism, and the activation mode. Therefore, it is important to design catalytic enantioselective reactions and identify suitable catalytic systems to construct a spirooxindole framework.



Scheme 1. Profile of catalytic enantioselective construction of spirooxindole skeletons.

Organocatalytic asymmetric transformations,⁹⁻¹⁰ especially multicomponent reactions, are considered robust methods for the enantioselective construction of frameworks with medicinal relevance, which can avoid transition-metal contamination of the products.¹¹ In addition, catalytic enantioselective [3+3] cyclizations, especially organocatalytic enantioselective multicomponent [3+3] cyclizations, have proven to be efficient strategies for constructing chiral six-membered rings in a single step.¹² To construct a tetrahydroquinolin-5-one-based spirooxindole scaffold in an enantioselective fashion, and due to our continuous interest in organocatalytic enantioselective

transformations,¹³ we designed an organocatalytic enantioselective multicomponent [3+3] cyclization (Scheme 2). In this design, we envisioned the three-component reaction of cyclic enaminone 1, isatin 2, and malononitrile 3 could be catalyzed by a tertiary amine-based bifunctional catalyst, which could form multiple hydrogen bonds with enaminone 1 and intermediate A to facilitate an enantioselective Michael addition and subsequent intramolecular nucleophilic addition of the intermediate B, thus constructing the desired tetrahydroquinolin-5-one-based spirooxindole scaffold in an enantioselective fashion.

This work: the first catalytic asymmetric construction of tetrahydroquinolin-5-one-based spirooxindole scaffold



Scheme 2. Design of the catalytic asymmetric reaction for the construction of an enantioenriched tetrahydroquinolin-5-one-based spirooxindole scaffold.

Herein, we report the first catalytic asymmetric construction of a chiral tetrahydroquinolin-5-one-based spirooxindole scaffold (up to 99% yield, 97:3 er) that takes advantage of the three-component [3+3] cyclization of enaminone, isatin, and malononitrile in the presence of a chiral bifunctional organocatalyst. This reaction also represents the first catalytic enantioselective version of this type of three-component [3+3] cyclization.

Results and Discussion

To test the feasibility of our hypothesis, the reaction of dimedone-derived enaminone 1a, *N*-benzyl substituted isatin 2a, and malononitrile 3 was used as a model reaction in the presence of chiral cinchona alkaloid catalyst 5a. which smoothly afforded the desired tetrahydroquinolin-5-one-based spirooxindole 4aa, but in a moderate yield and with low enantioselectivity (Table 1, entry 1). A series of bifunctional catalysts, 5b-5i, derived from various cinchona alkaloids¹⁴ were screened (entries 2-9). Although the yields were still unsatisfactory, cinchona alkaloid derivatives 5b and 5d bearing two hydroxyl groups were superior to others in controlling the enantioselectivity (entries 2 and 4 vs. entries 1, 3 and 5-9), which may be attributed to the action of the two hydroxyl groups in forming multiple hydrogen bonds with enaminone 1 and intermediate A. In particular, catalyst 5d afforded the product with the highest level of enantioselectivity (entry 4 vs. entry 2). Subsequently, screening the solvents showed that chloroform remained the best solvent, which delivered the reaction with the highest enantioselectivity of 79:21 er with a moderate yield of 46% (entry 4 vs. entries 10-14). Under this condition, the replacement of catalyst 5d by 5j resulted in further improved enantioselectivity of 88:12 er, but with no obvious enhancement in yield (entry 15 vs. entry 4). Besides, several chiral thiourea-tertiary amine and squaramide-tertiary amine catalysts 5k-5u were applied to the model reaction, but all showed lower catalytic activity than 5j in terms of the enantioselective control (see Supporting Information for details). Thus, catalyst 5j was selected as the optimal catalyst. To further improve the enantioselectivity and yield, different additives were evaluated in the presence of catalyst 5j (entries 15-18), which revealed that MgSO₄ was inferior to other additives with regard to the enantioselective control and yield (entry 18 vs. entries 15-17). Among these

additives, 4 Å molecular sieves (MS) were the most suitable, which could improve the yield to 81% with a retained enantioselectivity of 88:12 er (entry 17 vs. entries 15–16 and 18). When we increased the volume of the solvent from 0.5 to 2 mL, the enantioselectivity increased to 94:6 er albeit with a decreased yield (entry 20 vs. entries 18–19). Fortunately, when the molar ratio of reagents was changed to 1:1.5:1.5, the yield could be increased to 75% with a retained enantioselectivity (entry 21 vs. entry 20). However, when we further increased the volume of the solvent or lowered the reaction temperature, the yields decreased sharply with no improvement in enantioselectivity (entry 21 vs. entries 22–23). Finally, the best enantioselectivity of 96:4 er and the highest yield of 91% were obtained by modulating the molar ratio to 1:4:4 with a prolonged reaction time (entry 24).

Table 1. Screening of catalysts and optimization of reaction conditions^a.



9	5i	CHCl ₃	5 Å MS	20	49:51
10	5d	toluene	5 Å MS	22	77:23
11	5d	THF	5 Å MS	Trace	-
12	5d	CH ₃ CN	5 Å MS	38	52:48
13	5d	EtOAc	5 Å MS	Trace	-
14	5d	acetone	5 Å MS	Trace	-
15	5ј	CHCl ₃	5 Å MS	50	88:12
16	5ј	CHCl ₃	3 Å MS	62	82:18
17	5ј	CHCl ₃	4 Å MS	81	88:12
18	5ј	CHCl ₃	$MgSO_4$	47	81:19
19 ^d	5ј	CHCl ₃	4 Å MS	80	90:10
$20^{\rm e}$	5ј	CHCl ₃	4 Å MS	54	94:6
21 ^{e,f}	5ј	CHCl ₃	4 Å MS	75	94:6
22 ^{g,f}	5ј	CHCl ₃	4 Å MS	45	95:5
$23^{e,f,h}$	5ј	CHCl ₃	4 Å MS	43	94:6
$24^{e,f,i}$	5ј	CHCl ₃	4 Å MS	80	94:6
$25^{e,i,j}$	5ј	CHCl ₃	4 Å MS	91	96:4

^aUnless otherwise indicated, the reaction was performed at the 0.05 mmol scale and catalyzed by 10 mol% **5** in a solvent (0.5 mL) with additives (100 mg) at 10°C for 2 days, and the molar ratio of **1a:2a:3** was 1.2:1:1. ^bIsolated yield. ^cThe er value was determined by high-performance liquid chromatography (HPLC). ^dThe volume of solvent was 1 mL. ^eThe volume of solvent was 2 mL. ^fThe molar ratio of **1a:2a:3** was 1:1.5:1.5. ^gThe volume of solvent was 3 mL. ^hPerformed at 0°C. ⁱThe reaction time was 4 days. ^jThe molar ratio of **1a:2a:3** was 1:4:4.

After establishing the optimal reaction conditions, we investigated the substrate scope of this organocatalytic enantioselectivity multicomponent reaction. First, we examined the generality of enaminones **1** by the reaction with *N*-benzyl substituted isatin **2a** and malononitrile **3**. As shown in Table 2, this approach was applicable to a wide range of substrates **1** bearing different R^{1}/R^{2} groups, which afforded structurally diverse tetrahydroquinolin-5-one-based spirooxindoles **4** at generally high yields and excellent enantioselectivities (90:10 to 96:4 er). In detail, the electronic nature of the aniline moieties had no obvious effect on the enantioselectivity (entries 1–6). For example, in the cases of *meta*-substituted aniline-derived enaminones, both electron-donating groups such as methoxy (OMe) and electron-withdrawing groups such as fluorine (F) proved to be suitable substituents for enaminone substrates, which delivered the reaction in nearly identical

enantioselectivities (entries 5–6). However, the position of the substituents in the aniline moieties seemed to have effects on both the reactivity and enantioselectivity because *para*-substituted aniline-derived enaminones **1a–1d** showed higher reactivity and capability in enantioselective control than their *meta*-substituted counterparts **1e–1f** (entries 1–4 vs. entries 5–6). Substrate **1h** bearing a 2-naphthyl group could be utilized in this reaction at a high yield of 85% and a good enantioselectivity of 92:8 er (entry 8). Alkylamine-derived enaminones **1i** and **1j** successfully participated in this reaction to generate the corresponding [3+3] cyclization products with good enantioselectivities (entries 9–10). These results increase the applicability of this reaction. Apart from dimedone-derived enaminones, cyclohexanedione-derived enaminone **1k** could play a role in the reaction with a good enantioselectivity of 93:7 er (entry 11).

Table 2. Substrate scope of enaminones 1^a.

R ² R ²	+ NH R ¹	$ \begin{array}{c} $	$\frac{10 \text{ °C}}{\text{MS}} \xrightarrow{\text{O}}_{\text{R}^2} \xrightarrow{\text{N}}_{\text{R}^2} \xrightarrow{\text{N}}_{\text{R}^2}$	
entry	4	R^1/R^2	yield $(\%)^{b}$	er ^c
1	4aa	4-OMeC ₆ H ₄ /Me $(1a)$	91	96:4
2	4ba	$4-MeC_{6}H_{4}/Me(1b)$	99	93:7
3	4ca	$4-FC_{6}H_{4}/Me(1c)$	99	93:7
4	4da	$4-ClC_6H_4/Me(1d)$	99	94:6
5 ^d	4ea	3-OMeC ₆ H ₄ /Me (1e)	78	90:10
6	4fa	$3-FC_{6}H_{4}/Me$ (1f)	85	91:9
7	4ga	$C_{6}H_{5}/Me(1g)$	79	92:8
8	4ha	2-naphthyl/Me (1h)	85	92:8
9 ^e	4ia	Bn/Me (1i)	43	93:7
$10^{\rm e}$	4ja	<i>n</i> -C ₃ H ₇ /Me (1j)	71	90:10
11^{f}	4ka	4-OMeC ₆ H ₄ /H (1k)	45	93:7

^aUnless otherwise indicated, the reaction was performed at the 0.1 mmol scale and catalyzed by 10 mol% **5j** in chloroform (4 mL) at 10°C for 4 days, and the molar ratio of **1:2a:3** was 1:4:4. ^bIsolated yields. ^cThe *er* value was determined by HPLC. ^dPerformed at 0°C for 4 days. ^ePerformed at 70°C for 7 days. ^fPerformed at 50°C for 4 days.

Furthermore, in place of cyclic enaminones, ethyl acetoacetate-derived enaminone **11** was tentatively used as a substrate for this [3+3] cyclization under optimal conditions (eq 3); however, no desired spirooxindole **41a** was generated. Instead, pyran-based spirooxindole **6** was obtained in an acceptable enantioselectivity of 87:13 er, albeit with a low yield of 36%. The generation of product **6** may be ascribed to the instability of enaminone **11**, which easily decomposed into ethyl acetoacetate to undergo [3+3] cyclization.



Next, the substrate scope of isatins 2 was studied based on the reaction with enaminone 1a and malononitrile 3. As summarized in Table 3, this protocol was amenable to a series of isatins 2, which generated structurally diversified spirooxindoles 4 at overall high yields (60% to 91%) and with excellent enantioselectivities (90:10 to 96:4 er). We first investigated the effect of *N*-substituents of isatins 2 in the reaction (entries 1–5). Generally, *N*-benzyl-substituted isatins 2a–2c showed similar capability in enantioselective control with *N*-alkyl-substituted and *N*-allyl-substituted isatins 2d and 2e (entries 1–3 vs. entries 4–5). *N*-unprotected isatin 2f could play a role in this [3+3] reaction with a good enantioselectivity of 90:10 er and a high yield of 86% (entry 6). Next, a wide scope of isatins 2 bearing electronically different substituents at various positions of the phenyl moiety were applied to the [3+3] reactions (entries 7–12), which revealed that the position of the substituents influenced the enantioselectivity. For example,

C5-substituted isatins were inferior to C7-substituted isatins in terms of enantioselective control (entries 10–11 vs. entries 7–9). Moreover, apart from mono-substituted substrates, disubstituted isatin **21** could smoothly undergo the [3+3] cyclization in the highest enantioselectivity of 97:3 er (entry 12).

$ \begin{array}{c} $						
Entry	4	R^1/R^2	Yield $(\%)^{b}$	er ^c		
1	4aa	Bn/H (2a)	91	96:4		
2	4ab	<i>o</i> -FC ₆ H ₄ CH ₂ /H (2b)	87	93:7		
3 ^d	4ac	$C_{6}F_{5}CH_{2}/H$ (2c)	63	90:10		
4	4ad	Allyl/H (2d)	60	93:7		
5 ^d	4ae	Me/H (2e)	72	96:4		
6	4af	H/H (2f)	86	90:10		
7	4ag	Bn/5-OMe (2g)	84	90:10		
8	4ah	Bn/5-Me (2h)	74	94:6		
9 ^d	4ai	Bn/5-Br (2i)	82	90:10		
10	4aj	Bn/7-OMe (2j)	77	96:4		
11	4ak	Bn/7-Me (2k)	72	95:5		
12	4al	$Bn/5.7-Me_2(2l)$	66	97:3		

^aUnless indicated otherwise, the reaction was performed at the 0.1 mmol scale and catalyzed by 10 mol% **5j** in chloroform (4 mL) at 10°C for 4 days, and the molar ratio of **1a**:**2**:**3** was 1:4:4. ^bIsolated yields. ^cThe *er* value was determined by HPLC. ^dPerformed at 0°C for 4 days.

The absolute configuration of product **4aa** (>99:1 er after recrystallization) was determined to be (*R*) based on single crystal X-ray diffraction analysis (see the Supporting Information for details).¹⁵ Thus, the absolute configurations of other tetrahydroquinolin-5-one-based spirooxindoles **4** were assigned by analogy.

Based on the experimental results, we suggested a possible reaction pathway and activation mode to explain the stereochemistry of this three-component reaction. As exemplified by the formation of product **4aa** (Scheme 3), the Knoevenagel condensation of isatin **2a** with

malononitrile **3** in the presence of catalyst **5j** afforded an intermediate **A**.¹⁶ The intermediate **A** and dimedone-derived enaminone **1a** were simultaneously activated by chiral cinchona alkaloid **5j** through multiple hydrogen-bonding activation mode. This activation mode and the fixed orientation between the substrates and catalyst **5j** promoted an enantioselective Michael addition of dimedone-derived enaminone **1a** to the intermediate **A**, leading to the generation of another intermediate **B** with a fixed configuration. Subsequently, activated again by multiple hydrogen bonds between the catalyst **5j** and the intermediate **B**, this intermediate immediately underwent an intramolecular nucleophilic addition of the amino group to the cyano group, which resulted in the formation of the final product **4aa** with (*R*)-configuration.



Scheme 3. Suggested transition state and activation mode.

To verify our suggested reaction pathway, we performed a control experiment (Scheme 4). We monitored the reaction mixture, which revealed that the intermediate \mathbf{A} (isatylidene malononitrile \mathbf{A}) was rapidly generated within a short reaction time of 5 min. We then used isatylidene malononitrile \mathbf{A} as starting material to perform [3+3] cyclization with enaminone **1a** under standard conditions. As expected, this two-component reaction gave rise to the desired product **4aa** in the same enantioselectivity of 96:4 er with that of the three-component reaction.

This outcome demonstrated that the Knoevenagel condensation of isatins 2 with malononitrile 3 was indeed the first step of this one-pot three-component reaction.



Scheme 4. Control experiment.

Finally, to explore the potential of this approach, the model reaction was performed at a 1-mmol scale under standard conditions. As shown in eq. 4, compared with the small-scale reaction (Table 2, entry 1), the desired product **4aa** was obtained at a high yield of 91% and an excellent enantioselectivity of 96:4 er. This outcome indicated that this approach could be applicable for a large-scale synthesis of enantioenriched tetrahydroquinolin-5-one-based spirooxindoles. In addition, product **4aa** could be easily acylated by benzoyl chloride to generate compound **7** at a good yield of 92% and an almost retained enantioselectivity of 95:5 er (eq. 5).



Conclusions

Overall, we established the first catalytic enantioselective construction of a biologically important tetrahydroquinolin-5-one-based spirooxindole scaffold in high yields and with excellent enantioselectivities (up to 99% yield, 97:3 er) that takes advantage of chiral cinchona alkaloid-catalyzed enantioselective three-component reactions. Moreover, this reaction combined the merits of the multicomponent reaction and asymmetric organocatalysis, which realized the first catalytic enantioselective three-component [3+3] cyclization of cyclic enaminone, isatin, and malononitrile. Additionally, this reaction can be applied to large-scale synthesis of tetrahydroquinolin-5-one-based spirooxindoles in an enantioselective fashion. This synthetic methodology will not only provide an efficient approach for the construction of chiral tetrahydroquinolin-5-one-based spirooxindole scaffolds with biological importance but also increase our understanding of catalytic enantioselective three-component [3+3] cyclizations.

Experimental Section

¹H and ¹³C NMR spectra were measured at 400 and 100 MHz, respectively. The solvents used for NMR spectroscopy were CDCl₃, acetone- d_6 , and DMSO- d_6 , using tetramethylsilane as the internal reference. HRMS (ESI) was determined by a HRMS/MS instrument. Enantiomeric ratios (*er*) were determined by chiral high-performance liquid chromatography (chiral HPLC). The chiral columns used for the determination of enantiomeric ratios by chiral HPLC were Chiralpak AS-H, OD-H, AD-H and IA columns. Optical rotation values were measured with instruments operating at $\lambda = 589$ nm, corresponding to the sodium D line at the temperatures indicated. The X-ray source used for the single crystal X-ray diffraction analysis of compound **4aa** was CuK α (λ = 1.54178). Analytical grade solvents for the column chromatography were used after distillation.All starting materials commercially available were used directly.

Typical experimental procedure for the synthesis of products 4 and 6:

To the mixture of enaminones **1** (0.1 mmol), isatins **2** (0.4 mmol), malononitrile **3** (0.4 mmol), chiral catalyst **5j** (0.01 mmol) and 4 Å MS (100 mg) was added chloroform (4 mL). After being stirred at 10 $^{\circ}$ C for 4 days, the reaction mixture was filtered to remove the molecular sieves and the solid powder was washed with ethyl acetate. The resultant solution was concentrated under the reduced pressure to give the residue, which was purified through flash column chromatography on silica gel to afford pure products **4** or **6**.

(R)-2'-amino-1-benzyl-1'-(4-methoxyphenyl)-7',7'-dimethyl-2,5'-dioxo-5',6',7',8'-tetrahydr

o-1'*H*-spiro[indoline-3,4'-quinoline]-3'-carbonitrile (4aa): Flash column chromatography eluent, dichloromethane/ethyl acetate = 4/1; Reaction time = 4 d; yield: 91% (48.4 mg); white solid; m.p. 189–190 °C; $[\alpha]_D^{20} = +14.1$ (c 0.7, Acetone); ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.53 (d, *J* = 7.6 Hz, 2H), 7.38 – 7.30 (m, 2H), 7.30 – 7.27 (m, 1H), 7.25 – 7.19 (m, 2H), 7.13 (d, *J* = 7.2 Hz, 1H), 7.10 – 6.93 (m, 4H), 6.58 (d, *J* = 7.6 Hz, 1H), 5.11 (d, *J* = 16.0 Hz, 1H), 4.95 (d, *J* = 16.0 Hz, 1H), 4.29 (s, 2H), 3.85 (s, 3H), 2.20 (d, *J* = 16.0 Hz, 1H), 2.15 – 2.03 (m, 2H), 1.91 (d, *J* = 17.2 Hz, 1H), 0.97 (s, 3H), 0.92 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm): 194.7, 178.7, 160.7, 152.2, 151.1, 142.2, 136.1, 135.4, 131.0, 130.6, 128.7, 128.4, 127.8, 127.3, 127.2, 122.8, 122.7, 118.7, 116.0, 115.5, 111.1, 109.4, 62.7, 55.7, 49.7, 48.6, 44.5, 42.1, 32.5, 29.3, 27.0; IR (KBr): 3468, 2959, 2929, 2184, 1716, 1649, 1509, 1362, 1253, 758, 696; ESI FTMS exact mass calcd for (C₃₃H₃₀N₄O₃+H)⁺ requires m/z 531.2396, found m/z 531.2405; The enantiomeric ratio

The Journal of Organic Chemistry

(er) value: 96:4, determined by HPLC (Daicel Chiralpak AS-H, hexane/ isopropanol = 70/ 30, flow rate 1.0 mL/min, T = 30 °C, 254 nm): t_R = 5.860 (major), t_R = 8.613 (minor).

(R)-2'-amino-1-benzyl-7',7'-dimethyl-2,5'-dioxo-1'-(p-tolyl)-5',6',7',8'-tetrahydro-1'H-spiro

[indoline-3,4'-quinoline]-3'-carbonitrile (4ba): Flash column chromatography eluent, dichloromethane/ethyl acetate = 4/1; Reaction time = 4 d; yield: 99% (51.0 mg); white solid; m.p. 209–211 °C; $[\alpha]_D^{20} = +12.6$ (c 0.8, Acetone); ¹H NMR (400 MHz, CDCl₃) δ 7.55 (d, J = 7.2 Hz, 2H), 7.45 – 7.33 (m, 4H), 7.33 – 7.29 (m, 1H), 7.28 – 7.20 (m, 2H), 7.20 – 7.07 (m, 2H), 7.05 – 6.95 (m, 1H), 6.62 (d, J = 7.6 Hz, 1H), 5.14 (d, J = 16.0 Hz, 1H), 5.00 (d, J = 16.0 Hz, 1H), 4.19 (s, 2H), 2.49 (s, 3H), 2.29 – 2.18 (m, 1H), 2.18 – 2.07 (m, 2H), 1.93 (d, J = 17.2 Hz, 1H), 1.00 (s, 3H), 0.95 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm): 194.6, 178.6, 151.8, 150.7, 142.3, 141.0, 136.0, 135.3, 133.0, 131.4, 131.3, 129.5, 129.2, 128.7, 128.4, 127.3, 127.2, 122.8, 122.7, 118.5, 111.2, 109.4, 63.2, 49.8, 48.6, 44.6, 42.1, 32.5, 29.2, 27.0, 21.3; IR (KBr): 3445, 2958, 2355, 2335, 2182, 1716, 1645, 1362, 1185, 1152, 750, 694; ESI FTMS exact mass calcd for (C₃₃H₃₀N₄O₂+H)⁺ requires m/z 515.2447, found m/z 515.2439; The enantiomeric ratio (er) value: 93:7, determined by HPLC (Daicel Chiralpak AS-H, hexane/ isopropanol = 80/20, flow rate 1.0 mL/min, T = 30 °C, 254 nm): t_R = 7.330 (major), t_R = 11.077 (minor).

(*R*)-2'-amino-1-benzyl-1'-(4-fluorophenyl)-7',7'-dimethyl-2,5'-dioxo-5',6',7',8'-tetrahydro-1 '*H*-spiro[indoline-3,4'-quinoline]-3'-carbonitrile (4ca): Flash column chromatography eluent, dichloromethane/ethyl acetate = 4/1; Reaction time = 4 d; yield: 99% (51.2 mg); white solid; m.p. $320-321 \text{ }^{\circ}\text{C}$; $[\alpha]_{D}^{20} = +9.0$ (c 0.8, Acetone); ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.52 (d, *J* = 7.6 Hz, 2H), 7.44 – 7.29 (m, 5H), 7.26 – 7.18 (m, 2H), 7.15 – 7.05 (m, 2H), 7.03 – 6.93 (m, 1H), 6.60 (d, *J* = 8.0 Hz, 1H), 5.10 (d, *J* = 16.0 Hz, 1H), 4.95 (d, *J* = 16.0 Hz, 1H), 4.21 (s, 2H), 2.25 – 2.16 (m, 1H), 2.14 – 2.04 (m, 2H), 1.86 (d, J = 17.2 Hz, 1H), 0.97 (s, 3H), 0.92 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm): 194.6, 178.5, 163.2 (J = 251.2 Hz), 151.5, 150.7, 142.3, 135.9, 135.2, 132.0 (J = 8.6 Hz), 131.6, 131.6, 131.5, 128.7, 128.5, 127.3, 127.2, 122.8, 118.4, 117.9 (J = 26.8 Hz), 111.5, 109.5, 63.4, 49.7, 48.6, 44.6, 42.2, 32.5, 29.2, 27.0; IR (KBr): 3447, 3365, 2960, 2359, 2181, 1701, 1650, 1364, 1154, 1252, 758, 694; ESI FTMS exact mass calcd for ($C_{32}H_{27}FN_4O_2+H$)⁺ requires m/z 519.2196, found m/z 519.2208; The enantiomeric ratio (er) value: 93:7, determined by HPLC (Daicel Chiralpak AS-H, hexane/ isopropanol = 80/ 20, flow rate 1.0 mL/min, T = 30 °C, 254 nm): t_R = 8.363 (major), t_R = 16.387 (minor).

(*R*)-2'-amino-1-benzyl-1'-(4-chlorophenyl)-7',7'-dimethyl-2,5'-dioxo-5',6',7',8'-tetrahydro-1'*H*-spiro[indoline-3,4'-quinoline]-3'-carbonitrile (4da): Flash column chromatography eluent, dichloromethane/ethyl acetate = 4/1; Reaction time = 4 d; yield: 99% (53.2 mg); white solid; m.p. 278–280 °C; $[\alpha]_D^{20} = +19.3$ (c 0.7, Acetone); ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.58 – 7.48 (m, 4H), 7.39 – 7.31 (m, 3H), 7.26 – 7.21 (m, 1H), 7.15 – 7.05 (m, 3H), 7.01 – 6.95 (m, 1H), 6.61 (d, *J* = 7.6 Hz, 1H), 5.10 (d, *J* = 16.0 Hz, 1H), 4.96 (d, *J* = 16.0 Hz, 1H), 4.20 (s, 2H), 2.21 (d, *J* = 16.0 Hz, 1H), 2.14 – 2.05 (m, 2H), 1.87 (d, *J* = 17.2 Hz, 1H), 0.98 (s, 3H), 0.93 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm): 194.6, 178.5, 151.2, 150.4, 142.3, 136.8, 135.9, 135.1, 134.2, 128.7, 128.5, 128.3, 127.3, 127.2, 127.0, 122.8, 122.8, 120.7, 118.3, 111.6, 109.5, 63.7, 49.7, 48.6, 44.6, 42.2, 32.6, 29.2, 27.0; IR (KBr): 3056, 2957, 2358, 2185, 1716, 1649, 1360, 1091, 1015, 754, 696; ESI FTMS exact mass calcd for (C₃₂H₂₇CIN₄O₂+H)⁺ requires m/z 535.1901, found m/z 535.1923; The enantiomeric ratio (er) value: 94:6, determined by HPLC (Daicel Chiralpak AS-H, hexane/ isopropanol = 70/ 30, flow rate 1.0 mL/min, T = 30 °C, 254 nm): t_R = 5.510 (major), t_R = 8.027 (minor).

(*R*)-2'-amino-1-benzyl-1'-(3-methoxyphenyl)-7',7'-dimethyl-2,5'-dioxo-5',6',7',8'-tetrahydr o-1'*H*-spiro[indoline-3,4'-quinoline]-3'-carbonitrile (4ea): Flash column chromatography eluent, dichloromethane/ethyl acetate = 4/1; Reaction time = 4 d; yield: 78% (41.3 mg); white solid; m.p. 158–160 °C; $[\alpha]_D^{20} = +11.1$ (c 0.6, Acetone); ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.59 – 7.43 (m, 3H), 7.39 – 7.29 (m, 2H), 7.25 – 7.20 (m, 1H), 7.17 – 7.05 (m, 3H), 7.02 – 6.76 (m, 3H), 6.60 (d, *J* = 7.6 Hz, 1H), 5.11 (d, *J* = 16.0 Hz, 1H), 4.97 (d, *J* = 16.0 Hz, 1H), 4.23 (s, 2H), 3.87 (d, *J* = 9.6 Hz, 3H), 2.28 – 2.12 (m, 2H), 2.09 (d, *J* = 16.4 Hz, 1H), 1.96 (d, *J* = 17.2 Hz, 1H), 0.98 (s, 3H), 0.93 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm): 194.6, 178.6, 161.2, 151.5, 150.5, 142.3, 136.7, 136.0, 135.3, 131.5, 131.3, 128.7, 128.4, 127.2, 122.8, 121.8, 121.4, 118.5, 116.5, 115.7, 115.5, 115.2, 109.4, 63.1, 55.8, 49.8, 48.6, 44.6, 41.9, 32.6, 29.2, 27.0, 26.9; IR (KBr): 3441, 2961, 2186, 1716, 1645, 1362, 1259, 1021, 734; ESI FTMS exact mass calcd for (C₃₃H₃₀N₄O₃+H)⁺ requires m/z 531.2396, found m/z 531.2401; The enantiomeric ratio (er) value: 90:10, determined by HPLC (Daicel Chiralpak AS-H, hexane/ isopropanol = 80/ 20, flow rate 1.0 mL/min, T = 30 °C, 254 nm): t_R = 10.333 (major), t_R = 16.723 (minor).

(*R*)-2'-amino-1-benzyl-1'-(3-fluorophenyl)-7',7'-dimethyl-2,5'-dioxo-5',6',7',8'-tetrahydro-1 '*H*-spiro[indoline-3,4'-quinoline]-3'-carbonitrile (4fa): Flash column chromatography eluent, dichloromethane/ethyl acetate = 4/1; Reaction time = 4 d; yield: 85% (44.2 mg); white solid; m.p. 178-180 °C; $[\alpha]_D^{20} = +10.9$ (c 0.7, Acetone); ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.60 – 7.49 (m, 3H), 7.39 – 7.27 (m, 3H), 7.26 – 7.17 (m, 2H), 7.16 – 7.02 (m, 3H), 7.01 – 6.94 (m, 1H), 6.60 (d, *J* = 7.6 Hz, 1H), 5.10 (d, *J* = 16.0 Hz, 1H), 4.96 (d, *J* = 16.0 Hz, 1H), 4.22 (s, 2H), 2.25 – 2.11 (m, 2H), 2.07 (s, 1H), 1.89 (d, *J* = 17.2 Hz, 1H), 0.98 (s, 3H), 0.93 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm): 194.5, 178.4, 163.2 (*J* = 251.4 Hz), 151.2, 151.1, 150.3, 142.3, 137.1 (*J* = 9.3 Hz), 135.9, 135.1, 132.0, 128.7, 128.5, 127.3, 122.8, 118.3, 118.1 (J = 20.6 Hz), 111.6, 109.5, 63.7, 49.8, 48.6, 44.6, 42.0, 32.6, 29.1, 27.0; IR (KBr): 3648, 3586, 3326, 2957, 2359, 2189, 1705, 1652, 1362, 1175, 797, 660; ESI FTMS exact mass calcd for ($C_{32}H_{27}FN_4O_2+H$)⁺ requires m/z 519.2196, found m/z 519.2194; The enantiomeric ratio (er) value: 91:9, determined by HPLC (Daicel Chiralpak AS-H, hexane/ isopropanol = 80/ 20, flow rate 1.0 mL/min, T = 30 °C, 254 nm): t_R = 8.177 (major), t_R = 13.227 (minor).

(*R*)-2'-amino-1-benzyl-7',7'-dimethyl-2,5'-dioxo-1'-phenyl-5',6',7',8'-tetrahydro-1'*H*-spiro[indoline-3,4'-quinoline]-3'-carbonitrile (4ga): Flash column chromatography eluent, dichloromethane/ethyl acetate = 4/1; Reaction time = 4 d; yield: 79% (39.5 mg); white solid; m.p. 279–280 °C; $[\alpha]_D^{20}$ = +10.8 (c 0.6, Acetone); ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.62 – 7.51 (m, 5H), 7.40 – 7.30 (m, 4H), 7.24 (d, *J* = 7.2 Hz, 1H), 7.17 – 7.13 (m, 1H), 7.12 – 7.06 (m, 1H), 7.03 – 6.94 (m, 1H), 6.60 (d, *J* = 7.6 Hz, 1H), 5.12 (d, *J* = 16.0 Hz, 1H), 4.97 (d, *J* = 16.0 Hz, 1H), 4.18 (s, 2H), 2.27 – 2.10 (m, 2H), 2.09 – 2.03 (m, 1H), 1.94 – 1.81 (m, 1H), 0.96 (s, 3H), 0.92 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm): 194.6, 178.6, 151.6, 150.6, 142.3, 136.0, 135.8, 135.3, 130.8, 130.6, 129.9, 129.6, 128.7, 128.5, 128.4, 127.3, 127.2, 122.8, 118.5, 111.3, 109.5, 63.3, 49.8, 48.6, 44.6, 42.1, 32.5, 29.2, 27.0; IR (KBr): 3471, 3310, 2958, 2360, 2196, 1640, 1363, 1153, 1048, 745, 699; ESI FTMS exact mass calcd for (C₃₂H₂₈N₄O₂+H)⁺requires m/z 501.2290, found m/z 501.2308; The enantiomeric ratio (er) value: 92:8, determined by HPLC (Daicel Chiralpak AS-H, hexane/ isopropanol = 80/ 20, flow rate 1.0 mL/min, T = 30 °C, 254 nm): t_R = 9.740 (major), t_R = 16.327 (minor).

(*R*)-2'-amino-1-benzyl-7',7'-dimethyl-1'-(naphthalen-1-yl)-2,5'-dioxo-5',6',7',8'-tetrahydro-1'*H*-spiro[indoline-3,4'-quinoline]-3'-carbonitrile (4ha): Flash column chromatography eluent,

The Journal of Organic Chemistry

dichloromethane/ethyl acetate = $4/1$; Reaction time = 4 d; yield: 85% (46.5 mg); white solid; m.p.
264–265 °C; $[\alpha]_D^{20} = +12.9$ (c 0.7, Acetone); ¹ H NMR (400 MHz, CDCl ₃) δ (ppm): 8.13 – 8.03 (m
1H), 8.03 – 7.83 (m, 3H), 7.75 – 7.60 (m, 2H), 7.53 (d, <i>J</i> = 7.6 Hz, 2H), 7.48 – 7.37 (m, 1H), 7.37
- 7.30 (m, 2H), 7.25 - 7.17 (m, 2H), 7.14 - 7.06 (m, 1H), 7.05 - 6.97 (m, 1H), 6.60 (d, <i>J</i> = 7.6 Hz,
1H), 5.15 – 5.05 (m, 1H), 4.95 (d, J = 16.0 Hz, 1H), 4.23 (d, J = 7.2 Hz, 2H), 2.28 – 2.06 (m, 3H),
$2.03 - 1.86$ (m, 1H), $0.98 - 0.86$ (m, 6H); ¹³ C NMR (100 MHz, Acetone- d_6) δ (ppm): 193.8, 178.2,
142.8, 136.9, 136.3, 133.7, 133.6, 130.6, 129.9, 128.4, 128.0, 127.7, 127.3, 127.3, 126.9, 123.2,
122.1, 118.5, 108.6, 68.8, 62.2, 54.6, 49.6, 48.8, 43.8, 41.8, 32.2, 31.1; IR (KBr): 3648, 3310
2958, 2359, 2183, 1716, 1646, 1361, 1260, 1173, 1101; ESI FTMS exact mass calcd for
$(C_{36}H_{30}N_4O_2+H)^+$ requires m/z 551.2447, found m/z 551.2462; The enantiomeric ratio (er) values
92:8, determined by HPLC (Daicel Chiralpak AS-H, hexane/ isopropanol = 90/ 10, flow rate 1.0
mL/min, T = 30 °C, 254 nm): t_R = 30.020 (major), t_R = 47.763 (minor).

(*R*)-2'-amino-1,1'-dibenzyl-7',7'-dimethyl-2,5'-dioxo-5',6',7',8'-tetrahydro-1'*H*-spiro[indoli ne-3,4'-quinoline]-3'-carbonitrile (4ia): Flash column chromatography eluent, dichloromethane/ethyl acetate = 4/1; Reaction time = 7 d; yield: 43% (22.1 mg); white solid; m.p. 269–271 °C; $[\alpha]_D^{20}$ = +13.3 (c 0.4, Acetone); ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.56 – 7.45 (m, 4H), 7.41 – 7.33 (m, 3H), 7.30 – 7.27 (m, 3H), 7.13 – 7.04 (m, 2H), 7.02 – 6.96 (m, 1H), 6.62 (d, *J* = 7.6 Hz, 1H), 5.11 (d, *J* = 16.0 Hz, 1H), 5.05 – 4.82 (m, 3H), 4.48 (s, 2H), 2.59 – 2.36 (m, 2H), 2.26 – 2.02 (m, 2H), 1.07 (s, 3H), 0.98 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm): 194.4, 178.8, 152.4, 151.9, 142.2, 135.9, 135.6, 135.2, 129.7, 128.7, 127.2, 125.2, 122.9, 118.6, 112.4, 109.5, 65.9, 49.4, 49.0, 48.3, 44.6, 40.7, 32.6, 28.7, 27.4; IR (KBr): 3438, 2963, 2360, 2184, 1652, 1363, 1261, 800, 668; ESI FTMS exact mass calcd for (C₃₃H₃₀N₄O₂+H)⁺ requires m/z 515.2447,

found m/z 515.2455; The enantiomeric ratio (er) value: 93:7, determined by HPLC (Daicel Chiralpak IA, hexane/ isopropanol = 70/ 30, flow rate 1.0 mL/min, T = 30 °C, 254 nm): $t_R = 16.653$ (minor), $t_R = 19.590$ (major).

(R)-2'-amino-1-benzyl-7',7'-dimethyl-2,5'-dioxo-1'-propyl-5',6',7',8'-tetrahydro-1'H-spiro[i ndoline-3,4'-quinoline]-3'-carbonitrile (4ja): Flash column chromatography eluent, dichloromethane/ethyl acetate = 4/1; Reaction time = 7 d; yield: 71% (32.9 mg); white solid; m.p. $250-251 \text{ °C}; [\alpha]_{D}^{20} = +28.0 \text{ (c } 0.6, \text{ Acetone}); ^{1}\text{H NMR} (400 \text{ MHz}, \text{CDCl}_{3}) \delta \text{ (ppm)}: 7.64 - 7.49 \text{ (m,})$ 2H), 7.45 – 7.35 (m, 2H), 7.33 – 7.26 (m, 1H), 7.16 – 7.05 (m, 1H), 7.04 – 6.94 (m, 2H), 6.62 (d, J = 7.6 Hz, 1H), 5.12 (d, J = 16.4 Hz, 1H), 4.98 (d, J = 16.4 Hz, 1H), 4.92 (s, 2H), 3.82 - 3.50 (m, 2H), 2.76 – 2.39 (m, 2H), 2.28 – 2.10 (m, 2H), 1.89 – 1.62 (m, 2H), 1.17 (s, 3H), 1.08 (s, 3H), 1.05 - 0.96 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm): 194.5, 179.3, 152.4, 152.1, 142.0, 135.9, 135.2, 128.8, 128.7, 128.4, 127.3, 127.2, 122.9, 122.8, 119.3, 112.3, 109.4, 64.9, 49.5, 48.9, 46.5, 44.6, 40.7, 32.5, 28.9, 27.7, 23.1, 11.0; IR (KBr): 3189, 2961, 2359, 2181, 1651, 1380, 1029, 734, 693; ESI FTMS exact mass calcd for $(C_{29}H_{30}N_4O_2+H)^+$ requires m/z 467.2447, found m/z 467.2457; The enantiomeric ratio (er) value: 90:10, determined by HPLC (Daicel Chiralpak OD-H, hexane/ isopropanol = 70/ 30, flow rate 1.0 mL/min, T = 30 °C, 254 nm): $t_R = 9.727$ (minor), $t_R =$ 34.767 (major).

(*R*)-2'-amino-1-benzyl-1'-(4-methoxyphenyl)-2,5'-dioxo-5',6',7',8'-tetrahydro-1'*H*-spiro[in doline-3,4'-quinoline]-3'-carbonitrile (4ka): Flash column chromatography eluent, dichloromethane/ethyl acetate = 4/1; Reaction time = 4 d; yield: 45% (22.8 mg); white solid; m.p. $181-182 \ ^{\circ}C$; $[\alpha]_{D}^{20} = +34.5$ (c 0.2, Acetone); ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.53 (d, *J* = 7.2 Hz, 2H), 7.40 - 7.31 (m, 3H), 7.30 - 7.27 (m, 1H), 7.26 - 7.21 (m, 1H), 7.17 - 7.12 (m, 1H),

7.12 – 7.03 (m, 3H), 7.02 – 6.95 (m, 1H), 6.59 (d, J = 7.6 Hz, 1H), 5.12 (d, J = 16.0 Hz, 1H), 4.99 (d, J = 16.0 Hz, 1H), 4.17 (s, 2H), 3.88 (s, 3H), 2.42 – 2.25 (m, 2H), 2.24 – 2.09 (m, 2H), 2.00 – 1.88 (m, 1H), 1.88 – 1.77 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm): 194.6, 178.7, 160.8, 153.9, 150.7, 142.3, 136.0, 135.4, 130.9, 130.6, 128.7, 128.4, 127.8, 127.2, 127.2, 122.9, 122.7, 118.5, 115.9, 115.5, 112.5, 109.4, 63.2, 55.7, 48.7, 44.6, 36.3, 28.6, 21.2; IR (KBr): 3361, 2963, 2359, 2178, 1705, 1635, 1261, 1022, 801, 694; ESI FTMS exact mass calcd for (C₃₁H₂₆N₄O₃+H)⁺ requires m/z 503.2083, found m/z 503.2098; The enantiomeric ratio (er) value: 93:7, determined by HPLC (Daicel Chiralpak AS-H, hexane/ isopropanol = 80/ 20, flow rate 1.0 mL/min, T = 30 °C, 254 nm): t_R = 15.467 (major), t_R = 23.407 (minor).

(R)-2'-amino-1-(2-fluorobenzyl)-1'-(4-methoxyphenyl)-7',7'-dimethyl-2,5'-dioxo-5',6',7',8'tetrahydro-1'*H*-spiro[indoline-3,4'-quinoline]-3'-carbonitrile (4ab): Flash column chromatography eluent, dichloromethane/ethyl acetate = 4/1; Reaction time = 4 d; yield: 87% (47.8 mg); white solid; m.p. 256–258 °C; $[\alpha]_D^{20} = +18.5$ (c 0.8, Acetone); ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.71 – 7.58 (m, 1H), 7.35 – 7.26 (m, 1H), 7.25 – 7.18 (m, 2H), 7.16 – 6.95 (m, 7H), 6.65 (d, J = 7.6 Hz, 1H), 5.17 – 4.95 (m, 2H), 4.24 (s, 2H), 3.87 (s, 3H), 2.27 – 2.09 (m, 2H), 2.09 – 2.03 (m, 1H), 1.97 – 1.87 (m, 1H), 0.97 (s, 3H), 0.92 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm): 194.7, 178.8, 160.7, 160.5 (*J* = 243.6 Hz), 152.2, 151.0, 142.0, 135.3, 130.9, 130.6, 129.6 (*J* = 3.6 Hz), 128.8 (*J* = 8 Hz), 128.5, 127.8, 124.6, 123.1, 122.9, 118.6, 115.8 (*J* = 47.2 Hz), 115.0, 114.8, 111.1, 108.9, 62.8, 55.7, 49.7, 48.7, 42.1, 37.7, 32.5, 29.2, 27.0; IR (KBr): 3472, 2957, 2328, 2148, 1716, 1649, 1609, 1511, 1362, 1252, 1028, 909, 758, 690; ESI FTMS exact mass calcd for $(C_{33}H_{29}FN_4O_3+H)^+$ requires m/z 549.2302, found m/z 549.2307; The enantiomeric ratio (er) value: 93:7, determined by HPLC (Daicel Chiralpak AS-H, hexane/ isopropanol = 80/20,

flow rate 1.0 mL/min, T = 30 °C, 254 nm): $t_R = 8.940$ (major), $t_R = 14.810$ (minor).

(*R*)-2'-amino-1'-(4-methoxyphenyl)-7',7'-dimethyl-2,5'-dioxo-1-((perfluorophenyl)methyl)-5',6',7',8'-tetrahydro-1'*H*-spiro[indoline-3,4'-quinoline]-3'-carbonitrile (4ac): Flash column chromatography eluent, dichloromethane/ethyl acetate = 4/1; Reaction time = 4 d; yield: 63% (39.0 mg); white solid; m.p. 220–221 °C; $[\alpha]_D^{20} = +11.0$ (c 0.6, Acetone); ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.28 – 7.18 (m, 3H), 7.15 – 7.09 (m, 1H), 7.08 – 6.98 (m, 3H), 6.93 (d, *J* = 7.6 Hz, 1H), 5.23 (d, *J* = 15.2 Hz, 1H), 4.83 (d, *J* = 15.2 Hz, 1H), 4.20 (s, 2H), 3.89 (s, 3H), 2.22 – 2.04 (m, 2H), 2.04 – 1.97 (m, 1H), 1.90 (d, *J* = 17.2 Hz, 1H), 0.96 (s, 3H), 0.91 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm): 194.5, 177.9, 160.7, 151.5 (*J* = 130.9 Hz), 138.4, 130.8 (*J* = 30.4 Hz), 128.6, 127.7, 123.1, 123.1, 117.9, 115.7 (*J* = 34.4 Hz), 110.9, 107.9, 62.5, 55.7, 49.6, 48.2, 42.0, 32.5, 32.0, 28.9, 27.1; IR (KBr): 3475, 3333, 2959, 2187, 1724, 1645, 1363, 1254, 1047, 954, 606; ESI FTMS exact mass calcd for (C₃₃H₂₅F₅N₄O₃+H)⁺ requires m/z 621.1925, found m/z 621.1952; The enantiomeric ratio (er) value: 90:10, determined by HPLC (Daicel Chiralpak IA, hexane/ isopropanol = 70/30, flow rate 1.0 mL/min, T = 30 °C, 254 nm): t_R = 14.587 (minor), t_R = 17.857 (major).

(*R*)-1-allyl-2'-amino-1'-(4-methoxyphenyl)-7',7'-dimethyl-2,5'-dioxo-5',6',7',8'-tetrahydro-1'*H*-spiro[indoline-3,4'-quinoline]-3'-carbonitrile (4ad): Flash column chromatography eluent, dichloromethane/ethyl acetate = 4/1; Reaction time = 4 d; yield: 60% (28.8 mg); white solid; m.p. $197-198 \ ^{\circ}C$; $[\alpha]_{D}^{20} = +7.7$ (c 0.6, Acetone); ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.33 – 7.27 (m, 1H), 7.25 – 7.17 (m, 2H), 7.14 – 7.09 (m, 1H), 7.09 – 7.04 (m, 2H), 7.03 – 6.97 (m, 1H), 6.83 (d, *J* = 7.6 Hz, 1H), 6.03 – 5.84 (m, 1H), 5.56 – 5.41 (m, 1H), 5.32 – 5.15 (m, 1H), 4.50 – 4.35 (m, 2H), 4.17 (s, 2H), 3.90 (s, 3H), 2.24 – 1.99 (m, 3H), 1.96 – 1.83 (m, 1H), 0.95 (s, 3H), 0.91 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm): 194.6, 178.1, 160.7, 152.0, 150.9, 142.3, 135.3, 131.7, 130.9, 130.6, 128.4, 127.8, 122.8, 122.6, 118.4, 117.5, 116.0, 115.5, 111.2, 109.2, 63.0, 55.7, 49.7, 48.5, 42.9, 42.1, 32.5, 29.2, 27.0; IR (KBr): 3315, 3213, 2958, 2924, 2185, 1719, 1650, 1509, 1363, 1252, 848, 605; ESI FTMS exact mass calcd for (C₂₉H₂₈N₄O₃+H)⁺ requires m/z 481.2239, found m/z 481.2254; The enantiomeric ratio (er) value: 93:7, determined by HPLC (Daicel Chiralpak AS-H, hexane/ isopropanol = 70/ 30, flow rate 1.0 mL/min, T = 30 °C, 254 nm): t_R = 5.773 (major), t_R = 8.960 (minor).

(*R*)-2'-amino-1'-(4-methoxyphenyl)-1,7',7'-trimethyl-2,5'-dioxo-5',6',7',8'-tetrahydro-1'*H*-s piro[indoline-3,4'-quinoline]-3'-carbonitrile (4ae): Flash column chromatography eluent, dichloromethane/ethyl acetate = 4/1; Reaction time = 4 d; yield: 72% (32.7 mg); white solid; m.p. 144–145 °C; $[\alpha]_D^{20}$ = +1.6 (c 0.6, Acetone); ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.33 – 7.27 (m, 1H), 7.27 – 7.18 (m, 2H), 7.11 (d, *J* = 7.2 Hz, 1H), 7.09 – 7.03 (m, 2H), 7.04 – 6.97 (m, 1H), 6.84 (d, *J* = 7.6 Hz, 1H), 4.16 (s, 2H), 3.90 (s, 3H), 3.30 (s, 3H), 2.15 (d, *J* = 16.0 Hz, 1H), 2.10 – 2.00 (m, 2H), 1.89 (d, *J* = 17.2 Hz, 1H), 0.95 (s, 3H), 0.90 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm): 194.6, 178.5, 160.7, 151.9, 150.9, 143.2, 135.3, 130.9, 130.6, 128.6, 127.8, 122.7, 122.6, 118.4, 116.0, 115.5, 111.3, 108.1, 62.9, 55.7, 49.7, 48.5, 42.1, 32.5, 29.1, 27.0, 26.7; IR (KBr): 3674, 3445, 2962, 2923, 2359, 2184, 1715, 1645, 1260, 801, 668; ESI FTMS exact mass calcd for (C₂₇H₂₆N₄O₃+H)⁺requires m/z 455.2083, found m/z 455.2096; The enantiomeric ratio (er) value: 96:4, determined by HPLC (Daicel Chiralpak AS-H, hexane/ isopropanol = 70/ 30, flow rate 1.0 mL/min, T = 30 °C, 254 nm): t_R = 7.297 (major), t_R = 12.977 (minor).

(*R*)-2'-amino-1'-(4-methoxyphenyl)-7',7'-dimethyl-2,5'-dioxo-5',6',7',8'-tetrahydro-1'*H*-spi ro[indoline-3,4'-quinoline]-3'-carbonitrile (4af): Flash column chromatography eluent, dichloromethane/ethyl acetate = 4/1; Reaction time = 4 d; yield: 86% (38.0 mg); white solid; m.p. 269–271 °C; $[\alpha]_D^{20}$ = +6.6 (c 0.2, Acetone); ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm): 10.21 (s, 1H), 7.43 (d, *J* = 7.2 Hz, 1H), 7.35 (d, *J* = 7.2 Hz, 1H), 7.24 – 7.07 (m, 4H), 7.00 – 6.86 (m, 1H), 6.76 (d, *J* = 7.6 Hz, 1H), 5.37 (s, 2H), 3.85 (s, 3H), 2.19 – 2.06 (m, 2H), 1.97 – 1.81 (m, 2H), 0.89 (s, 3H), 0.82 (s, 3H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ (ppm): 194.3, 180.0, 160.3, 152.8, 151.9, 141.9, 137.2, 131.7, 131.4, 128.6, 128.1, 123.6, 121.8, 119.5, 116.0, 115.6, 110.7, 109.3, 61.0, 56.0, 49.8, 48.9, 41.8, 32.5, 28.8, 27.1; IR (KBr): 3675, 3385, 2971, 2900, 2359, 1647, 1508, 1260, 1048, 880, 669; ESI FTMS exact mass calcd for (C₂₆H₂₄N₄O₃+Na)⁺ requires m/z 463.1746, found m/z 463.1731; The enantiomeric ratio (er) value: 90:10, determined by HPLC (Daicel Chiralpak AD-H, hexane/ isopropanol = 70/ 30, flow rate 1.0 mL/min, T = 30 °C, 254 nm): t_R = 21.313 (minor), t_R = 28.627 (major).

(*R*)-2'-amino-1-benzyl-5-methoxy-1'-(4-methoxyphenyl)-7',7'-dimethyl-2,5'-dioxo-5',6',7',8 '-tetrahydro-1'*H*-spiro[indoline-3,4'-quinoline]-3'-carbonitrile (4ag): Flash column chromatography eluent, dichloromethane/ethyl acetate = 4/1; Reaction time = 4 d; yield: 84% (46.8 mg); white solid; m.p. 199–200 °C; $[\alpha]_D^{20} = -13.4$ (c 0.9, Acetone); ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.52 (d, *J* = 7.2 Hz, 2H), 7.37 – 7.27 (m, 3H), 7.25 – 7.17 (m, 2H), 7.08 – 6.94 (m, 2H), 6.78 – 6.67 (m, 1H), 6.63 – 6.54 (m, 1H), 6.47 (d, *J* = 8.4 Hz, 1H), 5.13 – 4.83 (m, 2H), 4.25 (s, 2H), 3.85 (s, 3H), 3.69 (s, 3H), 2.21 (d, *J* = 16.4 Hz, 1H), 2.15 – 2.02 (m, 2H), 1.95 – 1.85 (m, 1H), 0.97 (s, 3H), 0.93 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm): 194.7, 178.3, 160.7, 156.0, 152.2, 151.0, 136.9, 136.1, 135.9, 130.9, 130.6, 128.6, 127.8, 127.3, 127.2, 118.6, 116.0, 115.5, 111.6, 111.3, 111.1, 109.6, 63.0, 55.7, 55.6, 49.7, 49.0, 44.6, 42.1, 32.5, 29.2, 27.1; IR (KBr): 3462, 3336, 2956, 2836, 2360, 1713, 1648, 1510, 1252, 804, 606, 563; ESI FTMS exact

The Journal of Organic Chemistry

mass calcd for $(C_{34}H_{32}N_4O_4+H)^+$ requires m/z 561.2502, found m/z 561.2515; The enantiomeric ratio (er) value: 90:10, determined by HPLC (Daicel Chiralpak AS-H, hexane/ isopropanol = 80/ 20, flow rate 1.0 mL/min, T = 30 °C, 254 nm): t_R = 13.013 (major), t_R = 25.820 (minor).

(*R*)-2'-amino-1-benzyl-1'-(4-methoxyphenyl)-5,7',7'-trimethyl-2,5'-dioxo-5',6',7',8'-tetrahy dro-1'*H*-spiro[indoline-3,4'-quinoline]-3'-carbonitrile (4ah): Flash column chromatography eluent, dichloromethane/ethyl acetate = 4/1; Reaction time = 4 d; yield: 74% (40.0 mg); white solid; m.p. 279–280 °C; $[\alpha]_D^{20} = +3.1$ (c 0.7, Acetone); ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.51 (d, *J* = 7.2 Hz, 2H), 7.38 – 7.28 (m, 3H), 7.25 – 7.19 (m, 2H), 7.11 – 7.00 (m, 2H), 6.95 – 6.77 (m, 2H), 6.47 (d, *J* = 8.0 Hz, 1H), 5.16 – 4.85 (m, 2H), 4.21 (s, 2H), 3.88 (s, 3H), 2.26 (s, 3H), 2.23 – 2.11 (m, 2H), 2.07 (s, 1H), 1.93 (d, *J* = 17.2 Hz, 1H), 0.98 (s, 3H), 0.94 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm):194.7, 178.6, 160.7, 152.0, 150.9, 139.9, 136.1, 135.4, 132.0, 131.0, 130.7, 128.8, 128.6, 127.9, 127.2, 127.1, 123.6, 118.7, 116.0, 115.5, 111.3, 109.1, 63.2, 55.7, 49.8, 48.7, 44.5, 42.1, 32.5, 29.1, 27.2, 21.3; IR (KBr): 3445, 2956, 2358, 2180, 1715, 1644, 1362, 1256, 1148, 1029, 806, 701; ESI FTMS exact mass calcd for (C₃₄H₃₂N₄O₃+H)^{*} requires m/z 545.2552, found m/z 545.2581; The enantiomeric ratio (er) value: 94:6, determined by HPLC (Daicel Chiralpak AS-H, hexane/ isopropanol = 70/ 30, flow rate 1.0 mL/min, T = 30 °C, 254 nm): t_R = 4.960 (major), t_R = 7.477 (minor).

(*R*)-2'-amino-1-benzyl-5-bromo-1'-(4-methoxyphenyl)-7',7'-dimethyl-2,5'-dioxo-5',6',7',8'-t etrahydro-1'*H*-spiro[indoline-3,4'-quinoline]-3'-carbonitrile (4ai): Flash column chromatography eluent, dichloromethane/ethyl acetate = 4/1; Reaction time = 4 d; yield: 82% (49.6 mg); white solid; m.p. 280–282 °C; $[\alpha]_D^{20}$ = -17.3 (c 1.0, Acetone); ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.50 (d, *J* = 7.2 Hz, 2H), 7.39 – 7.27 (m, 4H), 7.26 – 7.23 (m, 1H), 7.23 – 7.14 (m, 2H), 7.14 – 7.00 (m, 2H), 6.52 – 6.41 (m, 1H), 5.12 – 4.92 (m, 2H), 4.23 (s, 2H), 3.90 (s, 3H), 2.28 – 2.10 (m, 2H), 2.10 – 2.02 (m, 1H), 1.95 (d, J = 17.2 Hz, 1H), 0.99 (s, 3H), 0.95 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm): 194.7, 178.1, 160.8, 152.4, 151.0, 141.5, 137.3, 135.5, 131.2, 130.9, 130.6, 128.8, 127.5, 127.4, 127.2, 126.1, 118.3, 116.0, 115.7, 115.4, 110.9, 110.7, 62.5, 55.8, 49.7, 48.8, 44.6, 42.1, 32.5, 28.9, 27.4; IR (KBr): 3451, 3312, 3211, 2956, 2603, 2359, 2186, 1720, 1640, 1362, 1028, 808, 698; ESI FTMS exact mass calcd for (C₃₃H₂₉BrN₄O₃+H)⁺ requires m/z 609.1501, found m/z 609.1511; The enantiomeric ratio (er) value: 90:10, determined by HPLC (Daicel Chiralpak AS-H, hexane/ isopropanol = 70/ 30, flow rate 1.0 mL/min, T = 30 °C, 254 nm): t_R = 5.853 (major), t_R = 11.587 (minor).

(R)-2'-amino-1-benzyl-7-methoxy-1'-(4-methoxyphenyl)-7',7'-dimethyl-2,5'-dioxo-5',6',7',8 '-tetrahydro-1'*H*-spiro[indoline-3,4'-quinoline]-3'-carbonitrile (4aj): Flash column chromatography eluent, dichloromethane/ethyl acetate = 4/1; Reaction time = 4 d; yield: 77% (42.9 mg); white solid; m.p. 209–211 °C; $[\alpha]_D^{20} = +24.9$ (c 0.8, Acetone); ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.50 (d, J = 7.2 Hz, 2H), 7.35 – 7.27 (m, 3H), 7.24 – 7.14 (m, 2H), 7.10 – 6.99 (m, 2H), 6.98 - 6.90 (m, 1H), 6.82 - 6.69 (m, 2H), 5.31 - 5.14 (m, 2H), 4.18 (s, 2H), 3.87 (s, 3H),3.53 (s, 3H), 2.26 - 2.09 (m, 2H), 2.06 (d, J = 6.4 Hz, 1H), 1.96 - 1.85 (m, 1H), 0.97 (s, 3H), 0.92(s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm): 194.5, 178.9, 160.7, 152.0, 150.9, 144.9, 139.0, 136.9, 131.0, 130.6, 130.5, 128.1, 128.0, 127.0, 126.3, 123.3, 118.6, 116.0, 115.7, 115.5, 112.9, 111.3, 63.3, 55.8, 55.7, 49.8, 48.7, 46.4, 42.1, 32.5, 29.2, 27.0; IR (KBr): 3442, 3273, 2955, 2836, 2359, 2183, 1655, 1254, 1029, 736, 633; ESI FTMS exact mass calcd for $(C_{34}H_{32}N_4O_4+H)^+$ requires m/z 561.2502, found m/z 561.2510; The enantiomeric ratio (er) value: 96:4, determined by HPLC (Daicel Chiralpak AS-H, hexane/ isopropanol = 80/20, flow rate 1.0 mL/min, T = $30 \,^{\circ}$ C,

254 nm): $t_R = 9.143$ (major), $t_R = 16.177$ (minor).

(*R*)-2'-amino-1-benzyl-1'-(4-methoxyphenyl)-7,7',7'-trimethyl-2,5'-dioxo-5',6',7',8'-tetrahy dro-1'*H*-spiro[indoline-3,4'-quinoline]-3'-carbonitrile (4ak): Flash column chromatography eluent, dichloromethane/ethyl acetate = 4/1; Reaction time = 4 d; yield: 72% (39.0 mg); white solid; m.p. 270–271 °C; $[\alpha]_D^{20} = +31.7$ (c 0.4, Acetone); ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.53 (d, *J* = 7.6 Hz, 2H), 7.43 – 7.35 (m, 2H), 7.34 – 7.30 (m, 1H), 7.28 – 7.17 (m, 2H), 7.13 – 7.00 (m, 3H), 6.99 – 6.86 (m, 2H), 5.42 – 5.20 (m, 2H), 4.19 (s, 2H), 3.91 (s, 3H), 2.32 – 2.18 (m, 4H), 2.17 – 2.06 (m, 2H), 1.94 (d, *J* = 17.2 Hz, 1H), 1.00 (s, 3H), 0.96 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm): 194.6, 179.6, 160.7, 151.9, 150.8, 140.5, 138.5, 136.3, 132.5, 130.9, 130.6, 128.7, 127.9, 126.7, 126.1, 122.8, 121.0, 119.7, 118.7, 116.0, 115.5, 111.6, 63.7, 55.7, 49.8, 48.1, 45.9, 42.1, 32.5, 29.3, 26.9, 18.7; IR (KBr): 3565, 2931, 2327, 2180, 1690, 1641, 1512, 1363, 1256, 849, 736; ESI FTMS exact mass calcd for (C₃₄H₃₂N₄O₃+H)⁺ requires m/z 545.2552, found m/z 545.2559; The enantiomeric ratio (er) value: 95:5, determined by HPLC (Daicel Chiralpak AS-H, hexane/ isopropanol = 80/ 20, flow rate 1.0 mL/min, T = 30 °C, 254 nm): t_R = 7.850 (major), t_R = 13.960 (minor).

(*R*)-2'-amino-1-benzyl-1'-(4-methoxyphenyl)-5,7,7',7'-tetramethyl-2,5'-dioxo-5',6',7',8'-tetr ahydro-1'*H*-spiro[indoline-3,4'-quinoline]-3'-carbonitrile (4al): Flash column chromatography eluent, dichloromethane/ethyl acetate = 4/1; Reaction time = 4 d; yield: 66% (36.7 mg); white solid; m.p. 272–273 °C; $[\alpha]_D^{20} = +26.9$ (c 0.7, Acetone); ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.50 (d, *J* = 7.6 Hz, 2H), 7.37 – 7.27 (m, 3H), 7.25 – 7.17 (m, 2H), 7.11 – 6.97 (m, 2H), 6.78 (s, 1H), 6.71 (s, 1H), 5.23 (s, 2H), 4.18 (s, 2H), 3.88 (s, 3H), 2.24 (s, 3H), 2.21 – 2.16 (m, 3H), 2.15 – 2.10 (m, 2H), 2.09 – 2.04 (m, 1H), 1.93 (d, *J* = 17.2 Hz, 1H), 0.97 (s, 3H), 0.94 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm): 194.7, 179.6, 160.7, 151.9, 150.7, 138.5, 138.0, 136.5, 133.1, 132.0, 131.0, 130.7, 128.7, 127.9, 126.7, 126.1, 121.8, 119.3, 118.8, 116.0, 115.5, 111.6, 63.8, 55.7, 49.8, 48.2, 45.9, 42.1, 32.5, 29.1, 27.1, 21.0, 18.6; IR (KBr): 3627, 2954, 2359, 2181, 1699, 1643, 1557, 1363, 1253, 1029, 930, 752, 668; ESI FTMS exact mass calcd for $(C_{35}H_{34}N_4O_3+H)^+$ requires m/z 559.2709, found m/z 559.2720; The enantiomeric ratio (er) value: 97:3, determined by HPLC (Daicel Chiralpak AS-H, hexane/ isopropanol = 80/ 20, flow rate 1.0 mL/min, T = 30 °C, 254 nm): $t_R = 6.527$ (major), $t_R = 11.353$ (minor).

(R)-ethyl

2'-amino-1-benzyl-3'-cyano-6'-methyl-2-oxospiro[indoline-3,4'-pyran]-5'-carboxylate (6): Flash column chromatography eluent, dichloromethane/ethyl acetate = 4/1; Reaction time = 4 d; yield: 36% (14.9 mg); white solid; m.p. 209–211 °C; $[\alpha]_D^{20} = +14.9$ (c 0.4, Acetone); ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.48 (d, J = 7.2 Hz, 2H), 7.40 – 7.33 (m, 2H), 7.31 (s, 1H), 7.24 – 7.11 (m, 2H), 7.08 – 6.99 (m, 1H), 6.77 – 6.71 (m, 1H), 5.12 (d, J = 15.6 Hz, 1H), 4.85 (d, J =14.8 Hz, 1H), 4.79 (s, 2H), 3.98 – 3.85 (m, 1H), 3.68 – 3.53 (m, 1H), 2.43 (s, 3H), 0.77 – 0.57 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm): 177.5, 164.6, 159.5, 158.5, 142.8, 135.5, 133.2, 129.1, 128.7, 127.7, 123.6, 123.2, 116.7, 109.3, 105.2, 61.0, 60.7, 44.6, 19.1, 13.3; IR (KBr): 3391, 2922, 2359, 2192, 1715, 1362, 1082, 794, 668; ESI FTMS exact mass calcd for (C₂₄H₂₁N₃O₄+H)⁺ requires m/z 416.1610, found m/z 416.1600; The enantiomeric ratio (er) value: 87:13, determined by HPLC (Daicel Chiralpak AS-H, hexane/ isopropanol = 80/ 20, flow rate 1.0 mL/min, T = 30 °C, 254 nm): t_R = 8.320 (major), t_R = 10.080 (minor).

Procedure for the synthesis of intermediate A: To the mixture of *N*-benzyl substituted isatin2a (3 mmol), malononitrile 3 (3 mmol), MgSO₄ (1 g) was added dichloromethane (20 mL). After

being stirred at r.t. for 1 h, the reaction mixture was filtered to remove the $MgSO_4$. The resultant solution was concentrated under the reduced pressure to give the residue, which was purified through flash column chromatography on silica gel to afford pure product **A**.

2-(1-benzyl-2-oxoindolin-3-ylidene)malononitrile (intermediate A): Flash column chromatography eluent, petroleum ether/ethyl acetate = 4/1; Reaction time = 1 h; yield: 86% (735.2 mg); purple solid; m.p. 200–202 °C; ¹H NMR (400 MHz, CDCl3) δ (ppm): 8.13 (d, J = 7.8 Hz, 1H), 7.46 (t, J = 7.6 Hz, 1H), 7.41 – 7.28 (m, 5H), 7.11 (t, J = 7.6 Hz, 1H), 6.78 (d, J = 8.0 Hz, 1H), 4.91 (s, 2H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm): 162.6, 149.2, 146.2, 137.6, 134.2, 129.1, 128.4, 127.5, 126.9, 123.9, 118.3, 112.3, 110.6, 82.9, 44.2; IR (KBr): 3492, 2228, 1719, 1612, 1593, 1470, 1348, 1110, 1084, 789, 629; ESI FTMS exact mass calcd for (C₁₈H₁₁N₃O+H)⁺ requires m/z 286.0980, found m/z 286.0982.

Procedure for the synthesis of compound 7: A newly distilled dichloromethane (1 mL) was added to the mixture of compound **4aa** (0.2 mmol) and DMAP (0.05 mol) in a dried reaction bottle. After Et₃N (0.8 mmol) was added, the reaction mixture was stirred at room temperature for 15 min. Then, benzoyl chloride (0.3 mmol) and distilled dichloromethane (1 mL) were added to the reaction mixture, which was stirred at room temperature for 2 days. After the completion of the reaction as indicated by TLC, 1 M HCl was added to the reaction mixture, which was further extracted by dichloromethane and dried by anhydrous Na₂SO₄. The resultant organic layer was concentrated under the reduced pressure to give the residue, which was purified through flash column chromatography on silica gel to afford pure product **7**.

(*R*)-N-(1-benzyl-3'-isocyano-1'-(4-methoxyphenyl)-7',7'-dimethyl-2,5'-dioxo-5',6',7',8'-tetr ahydro-1'*H*-spiro[indoline-3,4'-quinolin]-2'-yl)benzamide (7): Flash column chromatography eluent, Petroleum ether/ethyl acetate = 1/1; Reaction time = 2 d; yield: 70% (89.0 mg); white solid; m.p. 175–176 °C; $[\alpha]_D^{20}$ = -11.5 (c 0.2, Acetone); ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.52 (d, *J* = 7.3 Hz, 2H), 7.43 (d, *J* = 6.8 Hz, 2H), 7.33 (t, *J* = 7.6 Hz, 2H), 7.24 – 7.21 (m, 1H), 7.18 – 7.11 (m, 4H), 7.09 – 7.04 (m, 1H), 7.04 – 6.96 (m, 4H), 6.95 – 6.89 (m, 1H), 6.81 – 6.74 (m, 1H), 6.59 (d, *J* = 7.6 Hz, 1H), 5.19 (d, *J* = 16.0 Hz, 1H), 4.95 (d, *J* = 16.0 Hz, 1H), 3.75 (s, 3H), 2.30 (d, *J* = 16.0 Hz, 1H), 2.18 (d, *J* = 17.2 Hz, 1H), 2.12 (d, *J* = 16.0 Hz, 1H), 1.90 (d, *J* = 17.2 Hz, 1H), 0.99 (s, 3H), 0.94 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm): 194.8, 176.9, 169.7, 160.8, 152.5, 146.1, 142.0, 135.9, 134.0, 133.9, 132.6, 132.6, 131.3, 130.6, 129.3, 128.6, 128.0, 127.9, 127.3, 127.2, 115.4, 114.8, 111.1, 109.5, 91.6, 55.7, 50.9, 49.8, 44.8, 41.9, 32.5, 29.5, 26.6; IR (KBr): 3543, 3120, 2707, 2292, 1867, 1449, 1025, 612; ESI FTMS exact mass calcd for (C₄₀H₃₄N₄O₄+H)⁺ requires m/z 635.2658, found m/z 635.2660; The enantiomeric ratio (er) value: 95:5, determined by HPLC (Daicel Chiralpak OD-H, hexane/ isopropanol = 70/ 30, flow rate 1.0 mL/min, T = 30 °C, 254 nm): t_R = 7.510 (major), t_R = 15.377 (minor).

Acknowledgements

We are grateful for financial support from NSFC (21372002 and 21232007), TAPP, PAPD, Natural Science Foundation of Jiangsu province (BK20160003), and Undergraduate Students Project of JSNU.

Supporting Information

Screening of catalysts and optimization of reaction conditions, characterization data (including ¹H, ¹³C NMR and HPLC spectra) of products **4**, **6** and **7**, single crystal data of product **4aa**. This material is available free of charge via the Internet at <u>http://pubs.acs.org</u>.

- (1) For some selected examples: (a) Jossang, A.; Jossang, P.; Hadi, H. A.; Sevenet, T.; Bodo, B. J. Org. Chem. 1991, 56, 6527. (b) Cui, C. B.; Kakeya, H.; Osada, H. Tetrahedron 1996, 52, 12651. (c) Galliford, C. V.; Scheidt, K. A. Angew. Chem. Int. Ed. 2007, 46, 8748. (d) Murugan, R.; Anbazhagan, S.; Narayanan, S. S. Eur. J. Med. Chem. 2009, 44, 3272. (e) Kumari, G.; Nutan; Modi, M.; Gupta, S. K.; Singh, R. K. Eur. J. Med. Chem. 2011, 46, 1181. (f) Cao, Z.-Y.; Wang, X.; Tan, C.; Zhao, X.-L.; Zhou, J.; Ding, K. J. Am. Chem. Soc. 2013, 135, 8197. (g) Yin, X.-P.; Zeng, X.-P.; Liu, Y.-L.; Liao, F.-M.; Yu, J.-S.; Zhou, F.; Zhou, J. Angew. Chem. Int. Ed. 2014, 53, 13740.
- (2) For a recent review: (f) Singh, G. S.; Desta, Z. Y. Chem. Rev. 2012, 112, 6104.
- (3) (a) Ghozlan, S. A. S.; Mohamed, M. F.; Ahmed, A. G.; Shouman, S. A.; Attia, Y. M.;
 Abdelhamid, I. A. Arch. Pharm. 2015, 348, 113. (b) Goldfarb, D. S. U.S. Pat. Appl. Publ. 2009, US 20090163545 A1 20090625.
- (4) (a) Baharfar, R.; Azimi, R. J. Chem. Sci. 2015, 127, 1389. (b) Ansorge, S.; Bank, U.; Nordhoff,
 K.; Tager, M.; Striggow, F. PCT Int. Appl. 2005, WO 2005037257 A2 20050428.
- (5) For some selected examples: (a) Chen, H.; Shi, D.-Q. J. Comb. Chem. 2010, 12, 571. (b) Quiroga, J.; Portillo, S.; Perez, A.; Galvez, J.; Abonia, R.; Insuasty, B. Tetrahedron Lett. 2011, 52, 2664. (c) Hao, W.-J.; Wang, S.-Y.; Ji, S.-J. ACS Catal. 2013, 3, 2501. (d) Khalafi-Nezhad, A.; Mohammadi, S. ACS Comb. Sci. 2013, 15, 512. (e) Kang, S. R.; Lee, Y. R. Synthesis 2013, 45, 2593. (f) Mondal, A.; Mukhopadhyay, C. ACS Comb. Sci. 2015, 17, 404. (g) De, K.; Bhaumik, A.; Banerjee, B.; Mukhopadhyay, C. Tetrahedron Lett. 2015, 56, 1614.
- (6) (a) Yeung, B. K. S.; Zou, B.; Rottmann, M.; Lakshminarayana, S. B.; Ang, S. H.; Leong, S. Y.;

Tan, J.; Wong, J.; Keller-Maerki, S.; Fischli, C.; Goh, A.; Schmitt, E. K.; Krastel, P.; Francotte,
E.; Kuhen, K.; Plouffe, D.; Henson, K.; Wagner, T.; Winzeler, E. A.; Petersen, F. R.; Brun;
Dartois, V.; Diagana, T. T.; Keller, T. H. *J. Med. Chem.* 2010, *53*, 5155. (b) Chinigo, G. M.;
Paige, M.; Grindrod, S.; Hamel, E.; Dakshanamurthy, S.; Chruszcz, M.; Minor, W.; Brown, M.
L. *J. Med. Chem.* 2008, *51*, 4620.

- (7) For some reviews: (a) Shen, K.; Liu, X.; Lin, L.; Feng, X. Chem. Sci. 2012, 3, 327. (b) Zhou,
 F.; Liu, Y.-L.; Zhou, J. Adv. Synth. Catal. 2010, 352, 1381. (c) Klein, J. E. M. N.; Taylor, R. J.
 K. Eur. J. Org. Chem. 2011, 6821. (d) Dou, X. W.; Lu, Y. X. Chem. Eur. J. 2012, 18, 8315. (e)
 Rios, R. Chem. Soc. Rev. 2012, 41, 1060. (f) Hong, L.; Wang, R. Adv. Synth. Catal. 2013, 355, 1023. (g) Cheng, D.; Ishihara, Y.; Tan, B.; Barbas III, C. F. ACS Catal. 2014, 4, 743.
- (8) For representative examples on the catalytic enantioselective synthesis of spirooxindoles using
 3-isothiocyanato oxindoles: (a) Chen, W.-B.; Wu, Z.-J.; Hu, J.; Cun, L.-F.; Zhang, X.-M.; Yuan
 W.-C. Org. Lett. 2011, 13, 2472; (b) Kato, S.; Yoshino, T.; Shibasaki, M.; Kanai, M.;
 Matsunaga S. Angew. Chem. Int. Ed. 2012, 51, 7007; (c) Wu, H.; Zhang, L.-L.; Tian, Z.-Q.;
 Huang, Y.-D.; Wang, Y.-M. Chem. Eur. J. 2013, 19, 1747; (d) Tan, F.; Lu, L.-Q.; Yang, Q.-Q.;
 Guo, W.; Bian, Q.; Chen, J.-R.; Xiao, W.-J. Chem. Eur. J. 2014, 20, 3415; (e) Kayal, S.;
 Mukherjee, S. Eur. J. Org. Chem. 2014, 6696; (f) Zhao, J.-Q.; Zhou, M.-Q.; Wu, Z.-J.; Wang,
 Z.-H.; Yue, D.-F.; Xu, X.-Y.; Zhang, X.-M.; Yuan, W.-C. Org. Lett. 2015, 17, 2238; (g) Kayal,
 S.; Mukherjee, S. Org. Lett. 2015, 17, 5508.
- (9) For selected reviews on organocatalytic asymmetric reactions: (a) Grondal, C.; Jeanty, M.;
 Enders, D. *Nat. Chem.* 2010, *2*, 167. (b) Zhou, J. *Chem. Asian J.* 2010, *5*, 422. (c) Li, J.-L.; Liu,
 T.-Y.; Chen, Y.-C. Acc. Chem. Res. 2012, 45, 1491. (d) Melchiorre, P. Angew. Chem. Int. Ed.

The Journal of Organic Chemistry

2012, 51, 9748. (e) Chauhan, P.; Mahajan, S.; Kaya, U.; Hack, D.; Enders, D. Adv. Synth.
Catal. 2015, 357, 253. (f) Wang, Y.; Lu, H.; Xu, P.-F. Acc. Chem. Res. 2015, 48, 1832. (g)
Zhang, L.; Fu, N.; Luo, S. Acc. Chem. Res. 2015, 48, 986. (h) Wang, T.; Han, X.; Zhong, F.;
Yao, W.; Lu, Y. Acc. Chem. Res., 2016, 49, 1369.

- (10) For selected recent examples: (a) Liu, Y.-L.; Wang, X.; Zhao, Y.-L.; Zhu, F.; Zeng, X.-P.; Chen, L.; Wang, C.-H.; Zhao, X.-L.; Zhou, J. Angew. Chem. Int. Ed. 2013, 52, 13735. (b) Manna, M. S.; Mukherjee, S. Chem. Sci. 2014, 5, 1627. (c) Manna, M. S.; Mukherjee, S. J. Am. Chem. Soc. 2015, 137, 130. (d) Yu, J.-S.; Liao, F.-M.; Gao, W.-M.; Liao, K.; Zuo, R.-L.; Zhou, J. Angew. Chem. Int. Ed. 2015, 54, 7381. (e) Ni, Q.; Xiong, J.; Song, X.; Raabe, G; Enders, D. Chem. Commun. 2015, 51, 14628. (f) Zou, L.-H.; Philipps, A. R.; Raabe, G; Enders, D. Chem. Eur. J. 2015, 21, 1004. (g) Yao, W.; Dou, X.; Lu, Y. J. Am. Chem. Soc. 2015, 137, 54. (h) Wang, T.; Yu, Z.; Hoon, D. L.; Phee, C. Y.; Lan, Y.; Lu, Y. J. Am. Chem. Soc. 2016, 138, 265.
- (11) For some reviews: (a) de Graaff, C.; Ruijter, E.; Orru, R. V. A. Chem. Soc. Rev. 2012, 41, 3969. (b) Pellissier, H. Adv. Synth. Catal. 2012, 354, 237.
- (12) For selected recent examples: (a) Tong, M.-C.; Chen, X.; Tao, H.-Y.; Wang, C.-J. Angew. Chem. Int. Ed. 2013, 52, 12377. (b) Guo, H.; Liu, H.; Zhu, F.-L.; Na, R.; Jiang, H.; Wu, Y.; Zhang, L.; Li, Z.; Yu, H.; Wang, B.; Xiao, Y.; Hu, X.-P.; Wang, M. Angew. Chem. Int. Ed. 2013, 52, 12641. (c) Huang, J.; Luo, S.; Gong, L. Acta Chim. Sin. 2013, 71, 879. (d) Dai, W.; Lu, H.; Li, X.; Shi, F.; Tu, S.-J. Chem. Eur. J. 2014, 20, 11382. (e) Chen, X.; Qi, Z.-H.; Zhang, S.-Y.; Kong, L.-P.; Wang, Y.; Wang, X.-W. Org. Lett. 2015, 17, 42. (f) Chen, X.; Zhang, J.-Q.; Yin, S.-J.; Li, H.-Y.; Zhou, W.-Q.; Wang, X.-W. Org. Lett. 2015, 17, 4188.
- (13) (a) Zhang, Y.-C.; Zhao, J.-J.; Jiang, F.; Sun, S.-B.; Shi, F. Angew. Chem. Int. Ed. 2014, 53,

13912. (b) Zhao, J.-J.; Sun, S.-B.; He, S.-H.; Wu, Q.; Shi, F. Angew. Chem. Int. Ed. 2015, 54, 5460. (c) Zhang, Y.-C.; Zhu, Q.-N.; Yang, X.; Zhou, L.-J.; Shi. F. J. Org. Chem. 2016, 81, 1681.

- (14) For a review: (a) Marcelli, T.; van Maarseveen, J. H.; Hiemstra, H. *Angew. Chem. Int. Ed.* **2006**, *45*, 7496. For some selected examples: (b) Chen, W.-B.; Wu, Z.-J.; Pei, Q.-L.; Cun, L.-F.; Zhang, X.-M.; Yuan, W.-C. *Org. Lett.* **2010**, *12*, 3132. (c) Guo, W.; Wang, X.; Zhang, B.; Shen, S.; Zhou, X.; Wang, P.; Liu, Y.; Li, C. *Chem. Eur. J.* **2014**, *20*, 8545. (d) Reddy, M. G.; Ko, C.-T.; Hsieh, K.-H.; Lee, C.-J.; Das, U.; Lin, W. J. Org. Chem. **2016**, *81*, 2420.
- (15) CCDC 1483323 for compound 4aa. See the Supporting Information for details.
- (16) For selected examples on isatylidene malononitrile A-involved enantioselective reactions: (a)
- Zhong, F.; Han, X.; Wang, Y.; Lu, Y. Angew. Chem. Int. Ed. 2011, 50, 7837. (b) Zhong, F.; Han,
- X.; Wang Y.; Lu, Y. Chem. Sci. 2012, 3, 1231. (c) Han, X.; Chan, W.-L.; Yao, W.; Wang, Y.; Lu,
- Y. Angew. Chem. Int. Ed. 2016, 55, 6492.